Podcasts on Status Epileptics and Self-Management in Veterans

This week, we are featuring two Hallway Conversations episodes: one is on status epilepticus, and the other is about self management, particuarly for veterans with seizures.

SAGE Trial for Refractory Status Epilepticus

In this episode of Epilepsy.com's Hallway Conversations, Dr. Joseph Sirven, Professor of Neurology at Mayo Clinic Arizona and Editor-in-Chief of Epilepsy.com, interviews Steve Kanes, MD, PhD, Chief Medical Officer at SAGE Therapeutics about the SAGE 547 Trial in Status Epilepticus. SAGE-547 is currently being evaluated in a Phase 1/2 clinical trial for super-refractory status epilepticus (SRSE). SAGE-547 demonstrated robust findings in preclinical models of SE, including significantly increased efficacy over current standard-of-care benzodiazepine treatment, and compelling early human experience data.

POEM Study

In this episode of Epilepsy.com's Hallway Conversations, Dr. Joseph Sirven, Professor of Neurology at Mayo Clinic Arizona and Editor-in-Chief of Epilepsy.com, interviews John Hixson, MD about the Policy for Optimal Epilepsy Management (POEM) study. The overall goal of the study is to improve the self-management practices of U.S. Veterans with epilepsy such as tracking seizures, managing medications and side effects, and engaging with other people with similar concerns about their condition. The results of the study were presented at the 66th Annual Meeting of the American Academy of Neurology.